Literature DB >> 29301754

Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148.

Jun Mori1, Zoltan Nagy1, Giada Di Nunzio1, Christopher W Smith1, Mitchell J Geer1, Rashid Al Ghaithi2, Johanna P van Geffen3, Silke Heising1, Luke Boothman1, Bibian M E Tullemans3, Joao N Correia1, Louise Tee1, Marijke J E Kuijpers3, Paul Harrison2, Johan W M Heemskerk3, Gavin E Jarvis4, Alexander Tarakhovsky5, Arthur Weiss6, Alexandra Mazharian1, Yotis A Senis1.   

Abstract

Src family kinases (SFKs) coordinate the initiating and propagating activation signals in platelets, but it remains unclear how they are regulated. Here, we show that ablation of C-terminal Src kinase (Csk) and receptor-like protein tyrosine-phosphatase CD148 in mice results in a dramatic increase in platelet SFK activity, demonstrating that these proteins are essential regulators of platelet reactivity. Paradoxically, Csk/CD148-deficient mice exhibit reduced in vivo and ex vivo thrombus formation and increased bleeding following injury rather than a prothrombotic phenotype. This is a consequence of multiple negative feedback mechanisms, including downregulation of the immunoreceptor tyrosine-based activation motif (ITAM)- and hemi-ITAM-containing receptors glycoprotein VI (GPVI)-Fc receptor (FcR) γ-chain and CLEC-2, respectively and upregulation of the immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptor G6b-B and its interaction with the tyrosine phosphatases Shp1 and Shp2. Results from an analog-sensitive Csk mouse model demonstrate the unconventional role of SFKs in activating ITIM signaling. This study establishes Csk and CD148 as critical molecular switches controlling the thrombotic and hemostatic capacity of platelets and reveals cell-intrinsic mechanisms that prevent pathological thrombosis from occurring.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29301754      PMCID: PMC5888341          DOI: 10.1182/blood-2017-02-768077

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  75 in total

1.  CD148 enhances platelet responsiveness to collagen by maintaining a pool of active Src family kinases.

Authors:  S Ellison; J Mori; A J Barr; Y A Senis
Journal:  J Thromb Haemost       Date:  2010-03-23       Impact factor: 5.824

2.  P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.

Authors:  Gerald J Spangrude; Daniel Lewandowski; Fabrizio Martelli; Manuela Marra; Maria Zingariello; Laura Sancillo; Rosa Alba Rana; Anna Rita Migliaccio
Journal:  Stem Cells       Date:  2015-10-23       Impact factor: 6.277

3.  Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor gamma-chain, Fyn, and Lyn to activate human platelets.

Authors:  S Falati; C E Edmead; A W Poole
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

4.  Chk, a Csk family tyrosine protein kinase, exhibits Csk-like activity in fibroblasts, but not in an antigen-specific T-cell line.

Authors:  D Davidson; L M Chow; A Veillette
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

5.  Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling.

Authors:  Katsue Suzuki-Inoue; David Tulasne; Yang Shen; Teresa Bori-Sanz; Osamu Inoue; Stephanie M Jung; Masaaki Moroi; Robert K Andrews; Michael C Berndt; Steve P Watson
Journal:  J Biol Chem       Date:  2002-04-09       Impact factor: 5.157

6.  Dominant role of the protein-tyrosine phosphatase CD148 in regulating platelet activation relative to protein-tyrosine phosphatase-1B.

Authors:  Jun Mori; Ying-Jie Wang; Stuart Ellison; Silke Heising; Benjamin G Neel; Michel L Tremblay; Steve P Watson; Yotis A Senis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

7.  The Src family kinases and protein kinase C synergize to mediate Gq-dependent platelet activation.

Authors:  Binggang Xiang; Guoying Zhang; Lucia Stefanini; Wolfgang Bergmeier; T Kent Gartner; Sidney W Whiteheart; Zhenyu Li
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

8.  The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.

Authors:  Marie-Pierre Gratacap; Valérie Martin; Marie-Cécile Valéra; Sophie Allart; Cédric Garcia; Pierre Sié; Christian Recher; Bernard Payrastre
Journal:  Blood       Date:  2009-06-03       Impact factor: 22.113

9.  Recruitment and activation of SHP-1 protein-tyrosine phosphatase by human platelet endothelial cell adhesion molecule-1 (PECAM-1). Identification of immunoreceptor tyrosine-based inhibitory motif-like binding motifs and substrates.

Authors:  C T Hua; J R Gamble; M A Vadas; D E Jackson
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

10.  Inhibition of the kinase Csk in thymocytes reveals a requirement for actin remodeling in the initiation of full TCR signaling.

Authors:  Ying Xim Tan; Boryana N Manz; Tanya S Freedman; Chao Zhang; Kevan M Shokat; Arthur Weiss
Journal:  Nat Immunol       Date:  2013-12-08       Impact factor: 25.606

View more
  15 in total

1.  Agonistic anti-CD148 monoclonal antibody attenuates diabetic nephropathy in mice.

Authors:  Keiko Takahashi; Rachel H Kim; Lejla Pasic; Lilly He; Shinya Nagasaka; Daisuke Katagiri; Tracy May; Akira Shimizu; Raymond C Harris; Raymond L Mernaugh; Takamune Takahashi
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-27

2.  Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice.

Authors:  Zoltan Nagy; Jun Mori; Vanesa-Sindi Ivanova; Alexandra Mazharian; Yotis A Senis
Journal:  Blood       Date:  2020-04-30       Impact factor: 22.113

3.  Csk/CD148 and platelet SFK activation: a balancing act!

Authors:  Jieqing Zhu
Journal:  Blood       Date:  2018-03-08       Impact factor: 22.113

4.  The Gp1ba-Cre transgenic mouse: a new model to delineate platelet and leukocyte functions.

Authors:  Zoltan Nagy; Timo Vögtle; Mitchell J Geer; Jun Mori; Silke Heising; Giada Di Nunzio; Ralph Gareus; Alexander Tarakhovsky; Arthur Weiss; Benjamin G Neel; Guillaume E Desanti; Alexandra Mazharian; Yotis A Senis
Journal:  Blood       Date:  2018-11-14       Impact factor: 22.113

5.  Heterozygous mutation SLFN14 K208N in mice mediates species-specific differences in platelet and erythroid lineage commitment.

Authors:  Rachel J Stapley; Christopher W Smith; Elizabeth J Haining; Andrea Bacon; Sian Lax; Vera P Pisareva; Andrey V Pisarev; Steve P Watson; Abdullah O Khan; Neil V Morgan
Journal:  Blood Adv       Date:  2021-01-26

Review 6.  Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out?

Authors:  Yotis A Senis; Alastair J Barr
Journal:  Molecules       Date:  2018-03-02       Impact factor: 4.411

7.  TULA-2 Deficiency Enhances Platelet Functional Responses to CLEC-2 Agonists.

Authors:  John C Kostyak; Benjamin R Mauri; Carol Dangelmaier; Akruti Patel; Yuhang Zhou; Johannes A Eble; Alexander Y Tsygankov; Steven E McKenzie; Satya P Kunapuli
Journal:  TH Open       Date:  2018-12-05

8.  Comparative Analysis of Microfluidics Thrombus Formation in Multiple Genetically Modified Mice: Link to Thrombosis and Hemostasis.

Authors:  Magdolna Nagy; Johanna P van Geffen; David Stegner; David J Adams; Attila Braun; Susanne M de Witt; Margitta Elvers; Mitchell J Geer; Marijke J E Kuijpers; Karl Kunzelmann; Jun Mori; Cécile Oury; Joachim Pircher; Irina Pleines; Alastair W Poole; Yotis A Senis; Remco Verdoold; Christian Weber; Bernhard Nieswandt; Johan W M Heemskerk; Constance C F M J Baaten
Journal:  Front Cardiovasc Med       Date:  2019-07-30

Review 9.  The (Patho)Biology of SRC Kinase in Platelets and Megakaryocytes.

Authors:  Lore De Kock; Kathleen Freson
Journal:  Medicina (Kaunas)       Date:  2020-11-24       Impact factor: 2.430

Review 10.  Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.

Authors:  Peng Zeng; Alvin Schmaier
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.